Sensorion to Participate in ARO 49th Annual Midwinter Meeting

Sensorion, a clinical-stage biotechnology company, will attend the Association for Research in Otolaryngology (ARO) 49th Annual Midwinter Meeting in San Juan, Puerto Rico, from February 7-11, 2026. The company's focus is on novel therapies for hearing loss disorders.

Arnaud Giese, Ph.D., Sensorion's Group Leader for Animal Pharmacology, is scheduled for a podium presentation on February 8, 2026, at 11:30am ET. The presentation will cover SENS-601, their gene therapy targeting Autosomal Recessive Non-Syndromic Deafness 1A (DFNB1A).

This highlights Sensorion's ongoing development and strategic partnerships aimed at combating hearing loss through genetic and pharmacological interventions. Their pipeline includes promising solutions like SENS-401, currently in Phase 2 trials for various hearing impairments.